Thumbnail Image
Item

Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)

Bagel, Jerry
; 
Nguyen, Tien Q.
; 
Lima, Hermenio
; 
Jain, Neal
; 
Pariser, David M.
; ; 
Yosipovitch, Gil
; 
Zhang, Haixin
; 
Chao, Jingdong
; 
Bansal, Shikha
... show 4 more
Citations
Altmetric:
Genre
Journal article
Date
2022-05-20
Advisor
Committee member
Group
Department
Dermatology
Subject
Atopic dermatitis
 Baseline
 Dupilumab
 Eczema
 Registry
Permanent link to this record
http://hdl.handle.net/20.500.12613/9655
Collections
Faculty/Researcher Works
Show all metadata
Files
Thumbnail Image
HsuEtAl-JournalArticle-2022-05.pdf
Adobe PDF, 573.41 KB
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.1007/s13555-022-00742-w
Abstract
Introduction: Dupilumab was initially approved in 2017 as the first biologic therapy for atopic dermatitis (AD). We characterized adults with AD initiating dupilumab in a real-world setting in the USA/Canada. Methods: PROSE is an ongoing, longitudinal, prospective, observational, multicenter registry of patients with AD initiating dupilumab per country-specific prescribing information. We report baseline data (day of first dupilumab injection) for patients enrolled from April 2018 through July 2019. Results: Among 315 patients (mean age 42.5 years, 55.2% female), the median AD duration was 17.0 years; 65.4% reported a history of type 2 inflammatory comorbidities (e.g., allergic rhinitis, asthma), and 93.3% reported treatment(s) for AD in the previous year, including topical corticosteroids (90.8%), systemic corticosteroids (36.2%), and nonsteroidal systemic therapies (14.0%). In total, 89.2% had an Overall Disease Severity score of 3 (moderate) or 4 (severe). Other mean disease severity scores included the following: Eczema Area and Severity Index 16.9 (range 0–72), body surface area affected 26.8%, Patient-Oriented Eczema Measure 18.5 (range 0–28), Dermatology Life Quality Index 12.7 (range 0–30), and pruritus Numerical Rating Scale score 6.9 (range 0–10). Conclusion: Patients initiating dupilumab have longstanding moderate-to-severe AD with significant disease burden and frequent type 2 comorbidities.
Description
Citation
Bagel, J., Nguyen, T.Q., Lima, H. et al. Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE). Dermatol Ther (Heidelb) 12, 1417–1430 (2022). https://doi.org/10.1007/s13555-022-00742-w
Citation to related work
Springer
Has part
Dermatology and Therapy, Vol. 12
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
Embedded videos
License
Attribution-NonCommercial CC BY-NC
cbn